leslie chong talks about imugene's abl partnership for vaxinia
Published 1 year ago • 887 plays • Length 4:50Download video MP4
Download video MP3
Similar videos
-
7:40
imugene limited (asx: imu) emergence 2024: presentation by leslie chong, managing director and ceo
-
8:29
imugene's leslie chong details eureka therapeutics collaboration
-
7:10
imugene ceo leslie chong speaks about the company's positive new data at the esmo asia congress 2022
-
6:20
md & ceo leslie chong discusses bile tract cancer study expansion & strategic partnership
-
4:45
leslie chong's first interview following our news imugene secured two fda ind approvals
-
4:28
imugene ltd ceo & managing director leslie chong speaks with juststocks
-
29:19
imugene celularity announce an exclusive strategic partnership to develop a novel oncolytic virus.
-
18:08
asx/ausbiz biotech unlocked with imugene ceo leslie chong
-
53:26
developing cancer cures through the asx | going public w leslie chong & paul hopper
-
25:35
investor webinar: azer-cel trial update, september 2024
-
9:07
juststocks speaks with imugene ceo and cf33 inventor on latest with company's clinical trials
-
9:16
imugene ceo leslie chong presents at wholesale investor's virtual showcase july 2020
-
6:40
imugene doses first patient in vaxinia phase 1 trial
-
5:39
imugene announces clinical trial supply agreement with merck kgaa and pfizer for her-vaxx
-
7:17
ceo leslie chong and coo dr bradley glover speak with juststocks video
-
9:07
leslie chong & dr yuman fong speak to juststocks on latest with oncarlytics & mast clinical trials
-
6:16
imugene's new cancer therapy cd19 (oncarlytics) considered the 'holy grail'
-
5:35
imugene's leslie chong outlines key strategic partnership with celularity
-
4:12
imugene's ceo interviewed on ausbiz detailing a clinical trial deal with merck germany and pfizer.
-
26:56
investor presentation post asx news: imugene and eureka therapeutics oncarlytics collaboration
-
25:53
imugene ceo leslie chong's presentation at the nwr virtual investor conference august 2021.